The effects of the CCL2-CCR2 axis were noted not only on breast tumor cells of different subtypes (e.g., TNBC and luminal-A) but also in mammary intra-ductal injection models that mimicked the ductal carcinoma in situ (DCIS) stage of disease. Here, CCR2 is linked to ductal breast carcinoma in situ.